Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AXSM Stock  USD 100.49  1.41  1.42%   
About 63% of all Axsome Therapeutics' investors are looking to take a long position. The analysis of overall sentiment of trading Axsome Therapeutics stock suggests that some investors are interested at this time. Axsome Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Axsome Therapeutics. Many technical investors use Axsome Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Total 3Q 2024 net product revenue of 104.8 million, representing 81 percent year-over-year growth Auvelity 3Q 2024 net product sales of 80.4 million,...

Read at globenewswire.com
Macroaxis News: globenewswire.com
  

Axsome Therapeutics Current Investor Sentiment

Panic Vs Confidence

63

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Axsome Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Axsome Therapeutics.

Axsome Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Axsome Therapeutics Fundamental Analysis

We analyze Axsome Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Axsome Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Axsome Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Axsome Therapeutics stock to make a market-neutral strategy. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics with similar companies.

Peers

Axsome Therapeutics Related Equities

CNTBConnect Biopharma   2.78   
0%
23.0%
ENTAEnanta Pharmaceuticals   2.22   
0%
18.0%
CRNXCrinetics Pharmaceuticals   1.39   
11.0%
0%
FOLDAmicus Therapeutics   1.71   
14.0%
0%
LGNDLigand Pharmaceuticals   2.26   
19.0%
0%
DSGNDesign Therapeutics   4.62   
38.0%
0%
ORICOric Pharmaceuticals   5.60   
47.0%
0%
LYELLyell Immunopharma   6.00   
50.0%
0%
RVMDRevolution Medicines   6.89   
57.0%
0%
PASGPassage Bio   11.88   
100.0%
0%
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Axsome Therapeutics Hype Analysis, Axsome Therapeutics Correlation and Axsome Therapeutics Performance.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.